摘要
目的观察孟鲁司特治疗哮喘的疗效及其对患者炎性因子、肺功能的影响。方法将哮喘患者89例随机分为观察组45例和对照组44例,对照组给予常规治疗,观察组在对照组治疗的基础上给予孟鲁司特治疗,比较2组患者临床疗效、治疗前后肺功能、炎性因子水平。结果观察组总有效率为97.8%明显高于对照组的88.6%,差异有统计学意义(P<0.05)。入院时2组肺功能指标比较差异无统计学意义(P>0.05),用药后2组肺功能均改善,且观察组优于对照组,差异均有统计学意义(P<0.05)。2组入院时肿瘤坏死因子(TNF-α)、白介素-10(IL-10)水平比较差异无统计学意义(P>0.05),用药后2组TNF-α、IL-10水平均明显改善,且观察组优于对照组,差异均有统计学意义(P<0.05)。结论孟鲁司特治疗哮喘疗效显著,能有效改善患者气道炎性反应及肺功能,值得临床推广应用。
Objective To observe the clinical effect of Montelukast in the clinical symptoms,inflammatory factors and pulmonary function for asthma patients. Methods 89 patients with asthma were randomly divided into observation group（ n =45） and control group（ n = 44）,the control group was given routine treatment,on the basis of the control group,the observation group was treated with montelukast,the clinical efficacy,before and after treatment of lung function,inflammatory factor levels of two groups were compared. Results The clinical effective rate of observation group（ 97. 8%） was higher than control group（ 88. 6%）（ P〈 0. 05）; Upon admission to hospital,the index of TNF-α,IL-10 and pulmonary function index for two groups was not significantly different（ P 〉0. 05）,after treatment,the clinical symptoms were improved,the index of inflammatory factors,PEF and FVC for observation group was better than control group（ P 〈0. 05）. Conclusion Montelukast has an obvious effect in asthma patients,can improve the inflammatory reactions,pulmonary function and clinical symptoms.
出处
《临床合理用药杂志》
2017年第31期11-12,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
炎性因子
哮喘
疗效
孟鲁司特
肺功能
Inflammatory factors
Asthma
Clinical effect
Montelukast
Pulmonary function
